Available IPD datapackage for study 'A Phase 2 Study Of SU011248 In The Treatment Of Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma'

The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe in
patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab
(Avastin) -based treatment.

本研究旨在验证舒尼替尼（SU011248）在既往接受过以贝伐珠单抗（bevacizumab，Avastin）为基础的治疗且治疗失败的肾细胞癌（RCC）患者中是否具有抗肿瘤活性与安全性。